Skip to content
Find Clinical Trials
Find Clinical Trials
Home » Find Clinical Trials » A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) as Monotherapy, in Combination With Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3), and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) as Monotherapy, in Combination With Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3), and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Share Print
Servier Protocol Code: SYM021-01 Sponsor: Symphogen A/S Clinicaltrials.gov Identifier: NCT03311412

Find a recruiting site

Name: Institut de Recherches Internationales Servier, Département des études cliniques
Phone number: +33 1 55 72 60 00
Results
English (USA)
English (USA)
Interventions / Treatments
  • Advanced Solid Tumor Malignancies
  • Lymphoma
  • Anti-PD-1
Other study id numbers
  • SYM021-01